Fisher Biosciences Partners With Alfa Laval To Provide Disposable Bioprocessing Systems
作者: 整理时间:2005-12-20
12/14/2005
Logan, UT - -Fisher Biosciences,
through its HyClone business, will partner with Alfa Laval to provide
single-use bioprocessing systems for Haemacure's new manufacturing
facility for Hemaseel(R) biological adhesives in Sarasota, Fla. These
bioprocessing systems are marketed and sold by Alfa Laval under an
exclusive agreement with HyNetics(R), a joint venture between Alfa
Laval and HyClone. The contract with Haemacure marks one of the first
major installations of HyNetics technology for large-scale
bioprocessing.
Haemacure has selected Alfa Laval to provide all of the detailed
engineering for its new facility as well as selection of the
production equipment. The core bioprocessing equipment for the
operation will be the HyNetics single-use mixing technology, which
features control fixtures and hardware manufactured by Alfa Laval and
disposable elements manufactured by HyClone.
The HyNetics systems will be used to produce Haemacure's
fibrin-sealant and thrombin products sold under the Hemaseel brand.
These products include Hemaseel(R) HMN fibrin sealant and Hemaseel(R)
Thrombin -- innovative biological adhesives and hemostats for acute
surgical-wound care.
"Our single-use, disposable bioprocessing system will provide
Haemacure with significant flexibility at reduced costs when compared
to traditional stainless-steel systems, thus increasing efficiency
significantly," said Leland Foster, chief executive officer of Fisher
Biosciences. "It eliminates cleaning validations and virtually
eliminates the risk of batch-to-batch contamination."
Marc Paquin, president and chief executive officer of Haemacure,
added: "The implementation of this technology allows Haemacure to
establish and operate a very cost-efficient facility and to be more in
control of its own destiny."
The manufacture of Haemacure products involves the processing of
human plasma, and the HyNetics systems will be used primarily in the
critical mixing operation. In the HyNetics system, all of the parts
that will come in contact with Haemacure product materials are
designed for single use.
In addition, HyClone will be providing Haemacure with its
proprietary disposable BioProcess Containers(TM), which can be used
for storage and transport of process materials, as well as other
disposable components that complement the HyNetics system.
"We are excited about the commitment of Haemacure to HyNetics
technology," said Foster. "Our goal is to provide completely
disposable systems for applications throughout the entire
bioprocessing stream -- from media hydration to bioreactors, to
protein separation and purification, to bulk-drug storage and final
filling operations."
Alfa Laval and HyClone have been working together for more than
three years in developing the HyNetics single-use mixing technology.
"We are extremely pleased with the Haemacure agreement because it
further validates the concept of disposable bioprocessing technology,"
said Bill Brydges, president of Alfa Laval BioKinetics, the company's
engineering division. "We look forward to continuing to work with
HyClone to bring this technology to the larger biopharmaceutical
market."
SOURCE: Haemacure
| 